Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-3-4
pubmed:abstractText
E4599 was a phase II/phase III trial, in which 878 patients with advanced non-small cell lung cancer were randomized to carboplatin + paclitaxel (PC arm) or PC + bevacizumab (BPC arm). Survival and progression-free survival were superior on the BPC arm. The rationale for markers used in this correlative study was based on elevated vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), soluble intercellular adhesion molecule (ICAM) and E-selectin in a variety of malignancies and changes in response to endothelial cell apoptosis.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1407-12
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18316562-Aged, pubmed-meshheading:18316562-Antibodies, Monoclonal, pubmed-meshheading:18316562-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18316562-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18316562-Carboplatin, pubmed-meshheading:18316562-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:18316562-Chemotherapy, Adjuvant, pubmed-meshheading:18316562-Disease-Free Survival, pubmed-meshheading:18316562-E-Selectin, pubmed-meshheading:18316562-Female, pubmed-meshheading:18316562-Fibroblast Growth Factor 2, pubmed-meshheading:18316562-Humans, pubmed-meshheading:18316562-Intercellular Adhesion Molecule-1, pubmed-meshheading:18316562-Lung Neoplasms, pubmed-meshheading:18316562-Male, pubmed-meshheading:18316562-Paclitaxel, pubmed-meshheading:18316562-Prospective Studies, pubmed-meshheading:18316562-Survival Rate, pubmed-meshheading:18316562-Vascular Endothelial Growth Factor A
pubmed:year
2008
pubmed:articleTitle
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
pubmed:affiliation
University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44016, USA. afshin.dowlati@case.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase III, Research Support, N.I.H., Extramural